Published On : October 2017 Pages : 105 Category: Biotechnology Report Code : HC10280
Industry Trend Analysis
In 2017, the global cell line development market was evaluated approximately USD 1.92 billion and is anticipated to reach around USD 6.41 billion while maintaining a compound annual growth rate (CAGR) of 11.44% during the forecast period owing to rising demand for effective therapeutics, technological advancements, and monoclonal antibodies in cancer treatment field. The patent ending of megahit drugs like Abilify, Lantus, Androgel, and Namenda are anticipated to encourage the admission of new biosimilars. In recent period averagely, approximately 15 fresh proteins counting recombinant and therapeutic are being permitted by the United States Food and Drug Administration (FDA) yearly. Hence, elevated demand for innovative vaccines, drugs, therapeutic proteins, and biosimilars is anticipated to fuel the expansion of the cell line development market during the forecast years. Additionally, rising vaccine manufacturing, rising healthcare spending levels, acceptance of regenerative drugs and increase in funding concerning to research and development in the biotechnology market are some of the factors likely to drive future growth of the global market.
Type Outlook and Trend Analysis
Depending on the type, the market is classified into recombinant, hybridomas, primary, and continuous. Since 2017, recombinant was the major revenue rendering section owing to its superior pertinence in biologics production, protein interactions and gene activation above traditional cell assay methods. Moreover, increasing demand for toxicity testing and drug screening are anticipated to boost growth for the segment. Hybridomas sectional growth is anticipated to be in synchronization with the recombinant section largely due to the ability of large-scale incessant antibody production.
Product Outlook and Trend Analysis
In 2017, reagents and media ruled the global market concerning revenue. Rising bioproduction demanding reagents and media, right from incubation until line preservation and price exhaustive nature are the driving factors during the forecast years. Reagents utilized are attachments and matrix factors, antibiotics, freezing and dissociation reagents, miscellaneous reagents, biological buffers, and cell separation. Nutrients which are necessary for proper growth of the growing cells, Salts, and media are active in rendering that. MEM media, DMEM media, RPMI media, medium 199, Hans F-10 media, and other classical ones are frequently utilized media in cell growth.
Source Outlook and Trend Analysis
In 2017, the mammalian source for product improvement ruled the global demand owing to rising implementation rates for the monoclonal antibodies production and its capability to articulate complex proteins like human beings. Additionally, improved expression systems, as well as technology for mammalian cell source expansion, are anticipated to boost the industry growth. There are around 4,000 mammalian lines existing and research is going on for the advent of few more.
Application Outlook and Trend Analysis
The applications segment includes the production of monoclonal antibodies, vaccines, research, and bioproduction; tissue engineering; and drug discovery toxicity testing. The products have key application in bioproduction including therapeutic proteins, vaccines, and other biologics production. Additionally, an increase in research and development activities, the advent of biosimilars as well as accessibility of technologically superior procedures for large-scale manufacturing of biologics is anticipated to boost the expansion of this application section in future.
Regional Outlook and Trend Analysis
In 2017, North American cell line development regional market was the leading with revenues of around USD 800 million. The existence of advanced medical infrastructure, encouraging government initiatives concerning to development of the product, and growing awareness regarding the curative application of monoclonal antibodies in the treatment of cancer are a few major driving factors. Asia Pacific regional market is projected to experience productive CAGR during the forecast period owing to the existence of high unused opportunities along with speedily rising awareness among patients about effective treatments for cancer as well as increasing trend of research outsourcing from developing countries like China and India.
Competitive Outlook and Trend Analysis
The key industry participants in the global cell line development market include Lonza Group AG, Selexis SA, Sartorius AG, Thermo Fisher Scientific Inc., GE Healthcare, American Type Culture Collection (ATCC), European Collection of Cell Cultures (ECACC), Corning Inc., Sigma-Aldrich Corporation, and WuXi AppTec Inc. The global market is characteristically competitive noticed by high market rivalries. Market players are determined to achieve competitive benefit by exploring the available unused opportunities.
The global cell line development market is segmented as follows –
By Product
By Application
By Type of Cell Lines
By Source:
By Region
Some of the key questions answered by the report are:
Market Classification
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increasing Demand for Monoclonal Antibodies
3.2.1.2. Significant Increase in Vaccine Production
3.2.2. Restraints
3.2.2.1. Complicated Regulatory Policies
3.2.3. Opportunities
3.2.3.1. Emerging Countries to offer Lucrative Growth Opportunities
4. Cell Line Development Market, By Product
4.1. Introduction
4.2. The Cell Line Development Market Assessment and Forecast, By Product, 2012-2022
4.3. Reagents and Media
4.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4. Accessories and Consumables
4.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5. Equipment
4.5.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
4.5.2. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.3. Centrifuges
4.5.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.4. Incubators
4.5.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.5. Storage Equipment
4.5.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.6. Bioreactors
4.5.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.7. Microscopes
4.5.7.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5. Cell Line Development Market, By Application
5.1. Introduction
5.2. The Cell Line Development Market Assessment and Forecast, By Application 2012-2022
5.3. Bioproduction
5.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.4. Toxicity Testing
5.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.5. Drug Discovery
5.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.6. Research
5.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.7. Tissue Engineering
5.7.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6. Cell Line Development Market, By Type of Cell Lines
6.1. Introduction
6.2. Cell Line Development Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
6.3. Continuous Cell Lines
6.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6.4. Recombinant Cell Lines
6.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6.5. Primary Cell Lines
6.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
6.6. Hybridomas
6.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
7. Cell Line Development Market, By Source
7.1. Introduction
7.2. Cell Line Development Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
7.3. Non Mammalian Cell Line
7.3.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
7.3.2. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
7.3.3. Amphibians
7.3.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
7.3.4. Insects
7.3.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
7.4. Mammalian Cell Line
7.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
8. Cell Line Development Market, By Region
8.1. Introduction
8.2. Cell Line Development Market Assessment and Forecast, By Region, 2012-2022 ($Million)
8.3. North America
8.3.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
8.3.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.3.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.3.4. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.3.5. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.3.6. U.S.
8.3.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.3.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.3.6.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.3.6.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.3.7. Canada
8.3.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.3.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.3.7.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.3.7.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.3.8. Mexico
8.3.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.3.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.3.8.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.3.8.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4. Europe
8.4.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
8.4.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.4. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.5. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.6. Germany
8.4.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.6.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.6.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.7. France
8.4.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.7.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.7.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.8. UK
8.4.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.8.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.8.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.9. Italy
8.4.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.9.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.9.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.10. Spain
8.4.10.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.10.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.10.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.10.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.4.11. Rest of Europe
8.4.11.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.4.11.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.4.11.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.4.11.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5. Asia-Pacific
8.5.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
8.5.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.4. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.5. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.6. Japan
8.5.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.6.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.6.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.7. China
8.5.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.7.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.7.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.8. Australia
8.5.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.8.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.8.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.9. India
8.5.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.9.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.9.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.10. South Korea
8.5.10.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.10.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.10.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.10.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.5.11. Rest of Asia-Pacific
8.5.11.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.5.11.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.5.11.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.5.11.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6. Rest of the World
8.6.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
8.6.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.3. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.4. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.5. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.6. Brazil
8.6.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.6.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.6.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.7. Turkey
8.6.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.7.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.7.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.7.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.8. Saudi Arabia
8.6.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.8.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.8.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.8.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.9. South Africa
8.6.9.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.9.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.9.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.9.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.10. United Arab Emirates
8.6.10.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.10.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.10.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.10.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
8.6.11. Others
8.6.11.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
8.6.11.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
8.6.11.3. Market Assessment and Forecast, By Type of Cell Lines, 2012-2022 ($Million)
8.6.11.4. Market Assessment and Forecast, By Source, 2012-2022 ($Million)
9. Company Profiles
9.1. General Electric Company
9.1.1. Business Overview
9.1.2. Product Portfolio
9.1.3. Key Financials
9.1.4. Strategic Developments
9.2. Thermo Fisher Scientific Inc.
9.2.1. Business Overview
9.2.2. Product Portfolio
9.2.3. Key Financials
9.2.4. Strategic Developments
9.3. The European Collection of Cell Cultures (ECACC)
9.3.1. Business Overview
9.3.2. Product Portfolio
9.3.3. Key Financials
9.3.4. Strategic Developments
9.4. Lonza Group AG
9.4.1. Business Overview
9.4.2. Product Portfolio
9.4.3. Strategic Developments
9.5. Sigma-Aldrich Corporation
9.5.1. Business Overview
9.5.2. Product Portfolio
9.5.3. Key Financials
9.5.4. Strategic Developments
9.6. WuXi AppTec
9.6.1. Business Overview
9.6.2. Product Portfolio
9.6.3. Key Financials
9.6.4. Strategic Developments
9.7. American Type Culture Collection
9.7.1. Business Overview
9.7.2. Product Portfolio
9.7.3. Key Financials
9.7.4. Strategic Developments
9.8. Sartorius AG
9.8.1. Business Overview
9.8.2. Product Portfolio
9.8.3. Key Financials
9.8.4. Strategic Developments
9.9. Corning Inc.
9.9.1. Business Overview
9.9.2. Product Portfolio
9.9.3. Key Financials
9.9.4. Strategic Developments
9.10. Selexis AG
9.10.1. Business Overview
9.10.2. Product Portfolio
9.10.3. Key Financials
9.10.4. Strategic Developments
9.11. Vista Biologicals Co.
9.11.1. Business Overview
9.11.2. Product Portfolio
9.11.3. Key Financials
9.11.4. Strategic Developments
9.12. EuBiologics Co., Ltd.
9.12.1. Business Overview
9.12.2. Product Portfolio
9.12.3. Key Financials
9.12.4. Strategic Developments
9.13. Paragon Bio services
9.13.1. Business Overview
9.13.2. Product Portfolio
9.13.3. Key Financials
9.13.4. Strategic Developments
List of Tables
Table 1.Global Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 2.Reagents and Media Market, By Region, 2012-2022 ($Million)
Table 3.Accessories and Consumables Market, By Region, 2012-2022 ($Million)
Table 4.Equipment Market, By Type, 2012-2022 ($Million)
Table 5.Equipment Market, By Region, 2012-2022 ($Million)
Table 6.Centrifuges Market, By Region, 2012-2022 ($Million)
Table 7.Incubators Market, By Region, 2012-2022 ($Million)
Table 8.Storage Equipment Market, By Region, 2012-2022 ($Million)
Table 9.Bioreactors Market, By Region, 2012-2022 ($Million)
Table 10.Microscopes Market, By Region, 2012-2022 ($Million)
Table 11.Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 12.Bioproduction Market, By Region, 2012-2022 ($Million)
Table 13.Toxicity Testing Market, By Region, 2012-2022 ($Million)
Table 14.Drug Discovery Market, By Region, 2012-2022 ($Million)
Table 15.Research Market, By Region, 2012-2022 ($Million)
Table 16.Tissue Engineering Market, By Region, 2012-2022 ($Million)
Table 17.Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 18.Continuous Cell Lines Market, By Region, 2012-2022 ($Million)
Table 19.Recombinant Cell Lines Market, By Region, 2012-2022 ($Million)
Table 20.Primary Cell Lines Market, By Region, 2012-2022 ($Million)
Table 21.Hybridomas Market, By Region, 2012-2022 ($Million)
Table 22.Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 23.Non Mammalian Cell Line Market, By Type, 2012-2022 ($Million)
Table 24.Non Mammalian Cell Line Market, By Region, 2012-2022 ($Million)
Table 25.Amphibians Market, By Region, 2012-2022 ($Million)
Table 26.Insects Market, By Region, 2012-2022 ($Million)
Table 27.Mammalian Cell Line Market, By Region, 2012-2022 ($Million)
Table 28.Cell Line Development Market, By Region, 2012-2022 ($Million)
Table 29.North America Cell Line Development Market, By Country, 2012-2022 ($Million)
Table 30.North America Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 31.North America Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 32.North America Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 33.North America Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 34.U.S. Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 35.U.S. Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 36.U.S. Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 37.U.S. Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 38.Canada Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 39.Canada Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 40.Canada Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 41.Canada Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 42.Mexico Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 43.Mexico Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 44.Mexico Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 45.Mexico Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 46.Europe Cell Line Development Market, By Country, 2012-2022 ($Million)
Table 47.Europe Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 48.Europe Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 49.Europe Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 50.Europe Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 51.Germany Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 52.Germany Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 53.Germany Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 54.Germany Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 55.France Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 56.France Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 57.France Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 58.France Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 59.UK Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 60.UK Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 61.UK Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 62.UK Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 63.Italy Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 64.Italy Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 65.Italy Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 66.Italy Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 67.Spain Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 68.Spain Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 69.Spain Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 70.Spain Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 71.Russia Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 72.Russia Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 73.Russia Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 74.Russia Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 75.Rest of Europe Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 76.Rest of Europe Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 77.Rest of Europe Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 78.Rest of Europe Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 79.Asia-Pacific Cell Line Development Market, By Country, 2012-2022 ($Million)
Table 80.Asia-Pacific Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 81.Asia-Pacific Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 82.Asia-Pacific Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 83.Asia-Pacific Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 84.Japan Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 85.Japan Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 86.Japan Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 87.Japan Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 88.China Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 89.China Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 90.China Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 91.China Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 92.Australia Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 93.Australia Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 94.Australia Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 95.Australia Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 96.India Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 97.India Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 98.India Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 99.India Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 100.South Korea Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 101.South Korea Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 102.South Korea Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 103.South Korea Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 104.Rest of Asia-Pacific Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 105.Rest of Asia-Pacific Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 106.Rest of Asia-Pacific Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 107.Rest of Asia-Pacific Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 108.Rest of the World Cell Line Development Market, By Country, 2012-2022 ($Million)
Table 109.Rest of the World Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 111.Rest of the World Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 112.Rest of the World Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 113.Rest of the World Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 114.Brazil Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 115.Brazil Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 116.Brazil Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 7.Brazil Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 117.Turkey Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 118.Turkey Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 119.Turkey Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 120.Turkey Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 121.Saudi Arabia Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 122.Saudi Arabia Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 123.Saudi Arabia Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 124.Saudi Arabia Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 125.South Africa Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 126.South Africa Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 127.South Africa Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 128.South Africa Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 129.United Arab Emirates Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 130.United Arab Emirates Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 131.United Arab Emirates Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 132.United Arab Emirates Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 133.Others Cell Line Development Market, By Product, 2012-2022 ($Million)
Table 134.Others Cell Line Development Market, By Application, 2012-2022 ($Million)
Table 135.Others Cell Line Development Market, By Type of Cell Lines, 2012-2022 ($Million)
Table 136.Others Cell Line Development Market, By Source, 2012-2022 ($Million)
Table 137.General Electric Company: Key Strategic Developments, 2017-2017
Table 138.Thermo Fisher Scientific Inc.: Key Strategic Developments, 2017-2017
Table 139.The European Collection of Cell Cultures (ECACC): Key Strategic Developments, 2017-2017
Table 140.Lonza Group AG: Key Strategic Developments, 2017-2017
Table 141.Sigma-Aldrich Corporation: Key Strategic Developments, 2017-2017
Table 142.WuXi AppTec: Key Strategic Developments, 2017-2017
Table 143.American Type Culture Collection: Key Strategic Developments, 2017-2017
Table 144.Sartorius AG: Key Strategic Developments, 2017-2017
Table 145.Corning Inc.: Key Strategic Developments, 2017-2017
Table 146.Selexis AG: Key Strategic Developments, 2017-2017
Table 147.Vista Biologicals Co.: Key Strategic Developments, 2017-2017
Table 148.EuBiologics Co., Ltd.: Key Strategic Developments, 2017-2017
Table 149.Paragon Bio services: Key Strategic Developments, 2017-2017
List of Figures
Figure 1.Cell Line Development Market Share, By Product, 2012 & 2022 ($Million)
Figure 2.Cell Line Development Market Share, By Application, 2012 & 2022 ($Million)
Figure 3.Cell Line Development Market Share, By Type of Cell Lines, 2012 & 2022 ($Million)
Figure 4.Cell Line Development Market Share, By Source, 2012 & 2022 ($Million)
Figure 5.Cell Line Development Market, By Region, 2012 & 2022, ($Million)
Figure 6.GE Healthcare: Net Revenues, 2017-2017 ($Million)
Figure 7.GE Healthcare: Net Revenue Share, By Segment, 2017
Figure 8.GE Healthcare: Net Revenue Share, By Geography, 2017
Figure 9.Thermo Fisher Scientific, Inc.: Net Revenues, 2017-2017 ($Million)
Figure 10.Thermo Fisher Scientific, Inc.: Net Revenue Share, By Segment, 2017
Figure 11.Thermo Fisher Scientific, Inc.: Net Revenue Share, By Geography, 2017
Figure 12.Lonza Group AG: Net Revenues, 2017-2017 ($Million)
Figure 13.Lonza Group AG: Net Revenue Share, By Segment, 2017
Figure 14.Lonza Group AG: Net Revenue Share, By Geography, 2017
Figure 15.Sigma-Aldrich Corporation: Net Revenues, 2017-2017 ($Million)
Figure 16.Sigma-Aldrich Corporation: Net Revenue Share, By Segment, 2017
Figure 17.Sigma-Aldrich Corporation: Net Revenue Share, By Geography, 2017
Figure 18.Sartorius AG: Net Revenues, 2017-2017 ($Million)
Figure 19.Sartorius AG: Net Revenue Share, By Segment, 2017
Figure 20.Sartorius AG: Net Revenue Share, By Geography, 2017
Figure 21.Corning Inc.: Net Revenues, 2017-2017 ($Million)
Figure 22.Corning Inc.: Net Revenue Share, By Segment, 2017
Figure 23.Corning Inc.: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix |
Supply Side |
Demand Side |
Primary Data Sources |
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
Qualitative Data |
Quantitative Data (2017-2025) |
|
|